FDA Adds Brain Tumor Warning to Depo-Provera Birth Control Shot

In court filings, Pfizer said it first became aware of a possible link between Depo-Provera and meningioma in 2023. The company asked the FDA in early 2024 to add a warning to the drug’s label.

That request was initially denied, with the FDA saying existing studies did not clearly support a warning for all products containing medroxyprogesterone acetate (MPA), the drug used in the shot.